Global Infectious Disease Molecular Diagnostics Market Size Study, By Product (Instruments, Reagents), By Technology (Mass Spectrometry, PCR, In Situ Hybridization), By Application, By End-Use, and Regional Forecasts 2022-2032

The Global Infectious Disease Molecular Diagnostics Market is valued at approximately USD 52 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2024-2032. The increasing prevalence of infectious diseases worldwide, coupled with advancements in molecular diagnostic technologies, is propelling market growth. The growing demand for rapid and accurate disease detection methods, particularly in the wake of emerging infectious threats, has fueled investments in next-generation sequencing (NGS), polymerase chain reaction (PCR), and CRISPR-based diagnostic platforms. Additionally, technological innovations have significantly improved the precision, speed, and accessibility of diagnostic tests, enabling healthcare providers to make data-driven treatment decisions.

The rising incidence of diseases such as tuberculosis, hepatitis, sexually transmitted infections (STIs), respiratory illnesses, and antimicrobial-resistant infections has accelerated the adoption of molecular diagnostics. Government and private sector funding for infectious disease research, clinical trials, and innovative diagnostic tools are further amplifying market expansion. For instance, in January 2025, Rhode Island Hospital secured a USD 1 million grant from CARB-X to develop a direct-from-blood PCR test for pneumonia-causing bacteria. Similarly, Kryptos Biotechnologies received USD 1.2 million in funding to advance its rapid multiplex molecular diagnostic technology for STIs. These initiatives underscore the increasing focus on precision diagnostics to curb infectious disease outbreaks and improve patient outcomes.

Geographically, North America dominated the infectious disease molecular diagnostics market, accounting for a 40.95% revenue share in 2024. The region's strong foothold in diagnostic technologies, robust healthcare infrastructure, and high demand for rapid testing solutions contribute to its market leadership. The Asia-Pacific region is anticipated to witness the fastest CAGR over the forecast period, driven by rising disease prevalence, growing investments in diagnostic infrastructure, and increasing awareness about early disease detection. Countries such as China, India, and Japan are experiencing a surge in demand for molecular diagnostic tests due to their large patient populations, government funding for healthcare innovation, and advancements in home-based and point-of-care (PoC) testing solutions.

The growing adoption of artificial intelligence (AI) and digital health platforms in molecular diagnostics is expected to reshape the market landscape. AI-driven diagnostic tools enhance the accuracy and efficiency of pathogen detection, reducing false positives and improving diagnostic reliability. Additionally, cloud-based diagnostic platforms are streamlining real-time disease surveillance and outbreak management. With continued innovations in diagnostic technologies and increasing collaboration between public and private sector entities, the infectious disease molecular diagnostics market is poised for sustained growth throughout the forecast period.

Major Market Players Included in This Report Are:
• Abbott
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Hologic, Inc. (Gen-Probe)
• Illumina, Inc.
• Grifols S.A.
• Qiagen
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific
• PerkinElmer, Inc.

The Detailed Segments and Sub-Segments of the Market Are Explained Below:

By Product:
• Instruments
• Reagents
• Services

By Technology:
• Polymerase Chain Reaction (PCR)
Multiplex PCR
Other PCR
• In Situ Hybridization (ISH)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips and Microarrays
• Mass Spectrometry
• Transcription Mediated Amplification (TMA)
• Others

By Application:
• Respiratory Diseases
• Tuberculosis
• Meningitis
• Gastrointestinal Tract Infections
• Human Papillomavirus (HPV)
• Sexually Transmitted Infections (STIs)
• Sepsis
• Drug-Resistant Diseases
• Others

By End-Use:
• Hospitals
• Clinics
• Diagnostic Laboratories
• Research Institutes

By Region:

North America:
• U.S.
• Canada
• Mexico

Europe:
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia-Pacific:
• China
• Japan
• India
• Australia
• South Korea
• Thailand

Latin America:
• Brazil
• Argentina

Middle East & Africa (MEA):
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Years Considered for the Study Are as Follows:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years (2022-2032).
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape, including country-level insights.
• Competitive landscape featuring company profiles and strategic market positioning.
• Analysis of key business strategies, including mergers, acquisitions, and technological innovations.
• Demand-side and supply-side market analysis to highlight growth opportunities.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.